technetium tc 99m mertiatide has been researched along with Neuroendocrine Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beykan, S; Bluemel, C; Buck, AK; Hänscheid, H; Herrmann, K; Higuchi, T; Lapa, C; Lassmann, M; Lückerath, K; Scheurlen, M; Weich, A; Werner, RA | 1 |
1 other study(ies) available for technetium tc 99m mertiatide and Neuroendocrine Tumors
| Article | Year |
|---|---|
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Prognosis; Radiation Injuries; Retrospective Studies; Single Photon Emission Computed Tomography Computed Tomography; Technetium Tc 99m Mertiatide; Young Adult | 2016 |